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Role of uteroglobin G38A polymorphism in the progression ease has a variable clinical course and one third of the
of IgA nephropathy in Japanese patients. patients with IgAN progress to end-stage renal disease
Background. Uteroglobin is a multifunctional protein and (ESRD) within 10–20 years of the onset [2–4]. The patho-both its gene knockout and antisense transgenic mouse models
genesis of mesangial IgA deposition and the mechanismdevelop the pathological and clinical features of IgA nephropa-
of inter-individual differences in the rate of disease pro-thy. A genetic polymorphism in uteroglobin has been reported to
be associated with progression of IgA nephropathy in a Cauca- gression are still unclear [5]. An accumulating amount
sian population, but the findings remain controversial. of evidence suggests that genetic factors determine the
Methods. Genomic DNA was isolated from 595 individuals susceptibility to developing IgAN as well as to the pro-including 239 patients with IgAN, 160 patients with glomerulo-
gression of renal dysfunction [6, 7]. For the purpose ofnephritis distinct from IgAN, and 196 healthy controls. The
better understanding both the pathogenesis and theuteroglobin G38A genotype was determined by PCR-RFLP with
Sau96I. To examine the possible association of uteroglobin gene mechanism of IgAN progression, it is thought to be im-
polymorphism in the patients with and without IgAN, the uter- portant to identify the genetic background for the sus-
oglobin genotype and allele frequency were compared between
ceptibility both to IgAN and to ESRD. Poor prognosticthe two groups. In addition, associations between the polymor-
factors in clinical findings have been identified as highphism and blood pressure, proteinuria and prognosis of renal
function were analyzed in the patients with IgAN to investigate blood pressure, severe proteinuria, and a severe histolog-
the role of this gene polymorphism in the risk of progressive ical appearance of the renal biopsy [4, 8].
renal dysfunction in IgAN patients. Uteroglobin is mainly produced by mucosal epithelial
Results. The Cox proportional hazard regression model re-
cells and is present in both blood and urine [9, 10]. Uter-vealed that hypertension and proteinuria at the time of renal
oglobin is an evolutionarily conserved, steroid-inducible,biopsy were independent risk factors for poor renal survival.
Uteroglobin genotype was not significantly associated with the homodimeric molecule. It is a secreted protein with many
renal survival rate. However, in the patients with heavy protein- functions and potent immunomodulatory/anti-inflam-
uria (more than 2 g/day) or in those with hypertension at the matory properties [11]. Uteroglobin has a high affinity
time of renal biopsy, the renal survival of patients with the GG
for fibronectin and forms fibronectin-uteroglobin hetero-genotype was significantly worse than the other genotypes.
dimers, which counteract the fibronectin-collagen inter-Conclusion. Uteroglobin GG genotype may be a genetic
actions required for abnormal deposits [12]. The genera-marker for rapid disease progression to end-stage renal failure,
especially in the IgAN patients with heavy proteinuria or high tion of uteroglobin knockout mice has revealed that
blood pressure. disruption of this gene causes severe renal disease due
to abnormal deposits of fibronectin and collagen in the
glomeruli, as well as a lack of polychlorinated biphenyl
Immunoglobulin A nephropathy (IgAN), one of the binding and increased oxygen toxicity [13].
most prevalent forms of primary glomerulonephritis, is Thus, uteroglobin may be a good candidate for genetic
the major course of end-stage renal failure [1]. The dis- backgrounds, which influence the development and pro-
gression of IgAN. In fact, an association between genetic
polymorphism of uteroglobin and the rate of progres-Key words: IgA nephropathy, gene polymorphism, progressive renal
disease, end-stage renal disease, proteinuria, glomerulonephritis. sion, but not the development of disease, has been re-
ported in patients with IgAN from a Caucasian popula-Received for publication September 19, 2001
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phism in the development of IgAN, as well as in the ing region of exon 1. This polymorphism was reported
to be associated with a predisposition to asthma andsurvival of renal function in Japanese patients with IgA
nephropathy. with the progression of IgAN in a Caucasian population
[14–16]. Polymerase chain reaction (PCR) of the geno-
mic DNA was performed to amplify a 258-bp fragment
METHODS
in exon 1 of the uteroglobin gene using the primer pair
The ethics committee of the institution involved ap- 5-CAG TAT CTT ATG TAG AGC CC-3 and 5-CCT
proved the protocol for the study and informed written GAG AGT TCC TAA GTC CAG G-3. The reaction
consent for the genetic studies was obtained from all par- mixture contained 1  PCR buffer, 1.5 mmol/L MgCl2,
ticipants. Genomic DNA of peripheral blood cells was iso- 200 mmol/L deoxynucleotide triphosphates (dNTPs), 1
lated by an automatic DNA isolation system (NA-1000; unit Taq DNA polymerase (Takara, Kyoto, Japan), 10
Kurabo, Osaka, Japan) from 595 Japanese individuals pmol of each primer, and 50 to 100 ng genomic DNA.
including 239 patients with histologically confirmed IgAN. The PCR amplification reaction consisted of a cycle at
Henoch-Scho¨nlein purpura and secondary IgAN such 95C for five minutes, followed by 35 cycles of denatur-
as hepatic glomerulosclerosis were excluded from the ation at 94C for 15 seconds, annealing at 58C for 15
analysis. seconds, and extension at 72C for 30 seconds. A final
Diagnosis of IgAN was based on a kidney biopsy that extension was performed at 72C for five minutes. The
revealed the presence of dominant or co-dominant glo- PCR products were digested with restriction endonucle-
merular mesangial deposits of IgA as assessed by an im- ase Sau96I (New England Biolabs Inc., Beverly, MA,
munofluorescence examination. The others consist of 160 USA), and electrophoresed on 3% agarose gel. For 38G
patients with renal diseases which were confirmed histo- alleles, this resulted in a 128-bp and a 130-bp fragment,
logically to have no mesangial IgA deposition, including whereas the 258-bp 38A alleles lacked its restrictive site.
45 mesangial proliferative glomerulonephritis without
mesangial IgA deposition, 32 membranous nephropa- Statistical analysis
thy, 19 minor glomerular abnormality, 9 mesangioproli- Statview 5.0 statistical software (Abacus Concepts,
ferative glomerulonephritis, 8 thin basement membrane Inc. Berkeley, CA, USA) was used for statistical analyses
disease, 6 nephrosclerosis, 4 focal segmental glomerulo- on a Macintosh G4 computer. Chi-square analysis was
nephritis, and 37 other renal diseases (diabetic nephropa- used when comparing allele frequencies and categorical
thy, donor for kidney transplantation, primary amyloid- variables between the groups. Hardy-Weinberg equilib-
osis, and Alport syndrome, and other). The mean age rium was tested by a Chi-square test with 1 df. The Kaplan-
was 37.1 years old in patients with IgAN and 39.2 in Meier method and the Cox proportional hazards regres-
those with other glomerulonephritis. sion model analyzed the time course from renal biopsy
Clinical characteristics of the patients with IgAN in- to end point (initiation of dialysis or a doubling in the
cluding age, sex, duration of observation (in months), SCr level after the time of diagnosis). Covariates were
level of urinary protein excretion (g/day), serum creati- selected by a stepwise backward method and the effects
nine (SCr; mg/dL), and 24-hour creatinine clearance (mL/ of these covariates were expressed by a hazard ratio. P
min) were investigated. Hypertension was defined by the less than 0.05 was considered statistically significant.
use of one or more antihypertensive medications and/or
a blood pressure greater than or equal to 140 mm Hg
RESULTSsystolic or 90 mm Hg diastolic. The primary end point,
The 595 subjects consisting of 239 patients with histo-end-stage renal disease (ESRD), was defined as the date
logically proven IgAN, 160 with other glomerulonephri-at which the SCr levels doubled after the time of diagnosis,
tis distinct from IgAN, and 196 healthy controls wereor when patients underwent their first hemodialysis.
genotyped for uteroglobin G38A. Table 1 lists the geno-The administrations of glucocorticoids, antihyperten-
type distribution and the allele frequency of this genesive agents, and angiotensin-converting enzyme (ACE)
polymorphism in these groups. The allele frequency ofinhibitors also were recorded for each patient.
38G in uteroglobin for the Japanese population was 0.585To provide the control of local genotype frequency
(0.592 in IgAN patients, 0.563 in the patients with otherbeing examined, 196 Japanese volunteers (97 female and
glomerulonephritis, and 0.594 in the controls). These99 male) with no history of renal disease or hypertension
numbers were not statistically different between the pa-were recruited also.
tients with IgAN and those with other types of glomeru-
Determination of the genotypes lonephritis. Moreover, no difference was recognized in
the genotype and allele frequency between the patientsWe studied a single nucleotide polymorphism G38A
in the uteroglobin gene, which is located downstream with either IgAN or other glomerulonephritis and healthy
controls. The expected frequency of the genotypes infrom the transcription-initiation site within the noncod-
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Table 1. Frequencies of genotypes and alleles of the uteroglobin G38A gene polymorphism in patients with IgA nephropathy, those with
other glomerulonephritis, and controls without renal disease
IgAN Other GN Control
N239 N160 N196 2 P value
Genotype
AA 43 28 32
AG 109 84 95 1.086 0.298 (IgAN vs. other GN)
GG 87 48 69 0.237 0.888 (GN vs. controls)
Allele
A 0.408 0.437 0.406 0.687 0.407 (IgAN vs. other GN)
G 0.592 0.563 0.594 0.827 0.363 (GN vs. controls)
Abbreviations are: IgAN, IgA nephropathy; GN, glomerulonephritis.
Table 2. Clinical characteristics of patient with IgA nephropathy
All patients GG AG/AA
N239 N87 N152 P
Male sex % 46.4 51.7 43.4 NS
At the time of renal biopsy
Age years 37.113.6 35.513.2 38.013.8 NS
U protein g/day 1.31.3 1.31.3 1.41.3 NS
SCr mg/dL 1.00.6 1.10.9 1.00.4 NS
CCr mL/min 86.631.0 85.533.3 87.229.7 NS
Blood pressure mm Hg
Systolic 128.118.4 129.217.6 128.816.4 NS
Diastolic 77.213.3 78.012.4 77.310.9 NS
Hypertension % 40.6 56.3 31.6 0.072
During the observation
Observed periods months 95.866.8 93.772.4 96.663.5 NS
ESRD % 35.1 41.3 31.5 NS
Treatment
Glucocorticoid % 30.3 27.1 31.2 NS
Anti-HT drugs % 62.2 66.1 59.8 NS
ACEI % 50.0 44.0 53.8 NS
Abbreviations are: U protein, urinary protein; SCr, serum creatinine; CCr, creatinine clearance; ESRD, end-stage renal disease; anti-HT drug, antihypertensive drug;
ACEI, angiotensin I converting enzyme inhibitor.
each group, under the assumption of Hardy-Weinberg such as glucocorticoids, antihypertensives, or ACE in-
hibitors were not selected as a significant prognostic fac-equilibrium, did not differ from the observed genotype
frequencies. tor by this analysis. The genotype of uteroglobin G38A
polymorphism did not significantly affect the prognosisClinical characteristics of the patients with IgAN are
listed in Table 2. A comparison between patients either of renal function (GG vs. AG/AA; HR  1.327, 95%
CI, 0.828 to 2.126, P  0.240 by univariate analysis). Inhomozygous or heterozygous for A allele and those with
the GG genotype showed no significant differences in age, addition, the renal survival rate was not significantly
different between the two groups (Kaplan-Meier, 2 sex, SCr, creatinine clearance (CCr), blood pressure at the
time of renal biopsy, or in the percentage of cases treated 3.560, P  0.059; Fig. 1). The GG genotype was present
in a numerically greater proportion of patients withby ACE inhibitors. The incidence of hypertension in the
patients with GG genotype tended to be higher than ESRD, but the difference was not statistically significant
(OR, 1.53; P  0.083).that in those with other genotypes, although the differ-
ence was not statistically significant (P  0.072). Next, the role of uteroglobin G38A polymorphism on
the renal survival in the stratified patients with or withoutAmong all patients with IgAN (N  239), 84 (35.1%)
progressed to ESRD during the mean follow-up duration hypertension at the time of renal biopsy was examined
(Fig. 2). In the patients with hypertension (N  97),of 95.8  66.8 months. The Cox proportional hazard re-
gression (HR) model indicated proteinuria level of more the renal survival of patients with the uteroglobin GG
genotype was significantly worse than with other geno-than 2 g/day (HR  3.671, 95% CI, 2.19 to 6.16; P 
0.0001) and hypertension (HR  2.407, 95% CI, 1.22 to types (Kaplan-Meier, 2  4.320, P  0.038, Fig. 2A),
whereas no such difference was observed in the patients3.45; P  0.007) were independent risk factors for pro-
gression to ESRD (Table 3). These covariates were se- without hypertension (Kaplan-Meier, 2  0.071, P 
0.790, Fig. 2B).lected by stepwise backward analysis. Therapeutic agents
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Table 3. Cox proportional hazards regression model
Variable P value HR 95% CI
U protein
2.0 g/day 0.0001 3.671 2.19–616
1.0 g/day 0.054 0.535 0.28–1.01
HT at the time of renal biopsy 0.007 2.047 1.22–3.45
Abbreviations are: HR, hazard ratio; U protein, urinary protein; HT, hyper-
tension.
We also examined the effect of uteroglobin G38A
polymorphism in the subgroup of patients with a protein-
uria level of more than 2 g/day at the time of renal biopsy
because the Cox proportional hazard regression model
indicated that more than 2 g/day of proteinuria was a
significant risk factor for progression to ESRD. In this
analysis the renal survival of patients with the GG geno- Fig. 1. Renal survival in IgA nephropathy patients with the GG
(dashed line; N  87) and with AG/AA genotypes (solid line; N type was significantly poorer than with other genotypes
152) of uteroglobin G38A polymorphism. Kaplan-Meier, log rank test,(Kaplan-Meier, 2  6.030, P  0.014; Fig. 3A). The P  0.059.
50% survival time in patient with the GG genotype was
significantly shorter than that of the others (GG vs.
GA/AA; 61.0  12.8 months vs. 96.0  13.0 months).
This effect of uteroglobin G38A polymorphism was not hypertension and in those with heavy proteinuria (2
g/day). These factors were shown to be independent riskdetected in the patients with a proteinuria level of less
factors for poor renal survival in our patients using thethan 2 g/day at the time of renal biopsy (Kaplan-Meier,
Cox proportional hazard regression model. The ute-2 0.015, P  0.903; Fig. 3B).
roglobin G38A polymorphism has no association with
these risk factors themselves. If anything, the renal prog-
DISCUSSION nosis of the high-risk IgAN patients is further deterio-
Uteroglobin is an attractive candidate for the genetic rated when accompanied by the GG genotype. Thus,
study of IgAN development, because both its gene knock- the genetic polymorphism in uteroglobin may have an
out and its antisense transgenic mouse models developed influence on the sensitivity to these clinical risk factors.
the pathological features of IgAN [2, 12, 17]. However, Our present study could not detect a significant effect
the results of our study show that the genotype and allele of uteroglobin G38A polymorphism on the disease pro-
frequencies of uteroglobin G38A polymorphism were gression in any of the patients, although a previous study
not different between the patients with IgAN and those showed that the GG genotype of G38A uteroglobin poly-
with other glomerulonephritis distinct from IgAN, indi- morphism was more common in patients with progres-
cating that the genetic polymorphism investigated has sion [15]. This may be due to a difference in the frequency
no involvement in the development of IgAN. This result of the uteroglobin G38 allele within the analyzed popula-
is consistent with that of the previous studies in Cauca- tion, as the G38 allele frequency was lower in the Japa-
sian populations [14, 15]. nese population than in the Caucasian (0.585 vs. 0.682, re-
To investigate the risk factors for progression to spectively). Racial differences in allele frequencies might
ESRD, this study design employed a time-to-event ap- contribute to the conflicting results in association studies.
proach rather than an analysis of mean slope of renal Single nucleotide polymorphisms with high allele fre-
function, because a substantial proportion of our patients quencies were reported to be more statistically informa-
had stable or slowly declining renal function. In fact, tive than those with low allele frequencies in association
only one-third of the patients progressed to the end point studies [19].
during the follow-up period in this study. It has been There is also the possibility that patients with normal
suggested that an analysis of mean slope of renal function blood pressure and mild proteinuria are more frequent
is favored if a negligible proportion of patients have in this study, which may be due to a difference in the in-
stable or slowly declining renal function [18]. dication criteria of the renal biopsy. In fact, the mean
The significant and interesting finding in this study is blood pressure is lower in this study than in the previous
the effects of the G38A polymorphism in the uteroglobin report, although there was no difference in the mean
gene on the rate of IgAN disease progression, which were value of the urinary protein excretion. In addition, the
difference in therapeutic strategy may have an influenceobserved only in the stratified groups of patients with
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Fig. 2. Renal survival in IgA nephropathy
patients with (A, Kaplan-Meier, log rank test,
P 0.038) and without (B, Kaplan-Meier, log
rank test, P 0.790) hypertension at the time
of renal biopsy. Symbols are: (dotted line) GG
genotype; (solid line) AG/AA genotype. In
hypertensive patients (A), N  49 GG geno-
type and 48 AG/AA genotype. In IgA ne-
phropathy patients without hypertension (B),
N  38 GG genotype and 104 AG/AA geno-
type.
Fig. 3. Renal survival in IgA nephropathy
patients with (A, Kaplan-Meier, log rank test,
P 0.014) and without (B, Kaplan-Meier, log
rank test, P  0.903) a proteinuria level of
more than 2 g/day at the time of renal biopsy.
Symbols are: (dotted line) GG genotype;
(solid line) AG/AA genotype. In the patients
with 2 g/day proteinuria (A), N  29 GG
genotype and 49 AG/AA genotype. In pa-
tients with 	2 g/day proteinuria (B), N  58
GG genotype and 103 AG/AA genotype.
on the role of genetic polymorphism in disease progres- showed by the G gene construct [14]. The results of our
sion. In the present study 30.3% of the patients were study suggests that high blood pressure or heavy protein-
treated with glucocorticoids, although no information uria affects the level of uteroglobin, because the genetic
about the glucocorticoid therapy in the previous report polymorphism investigated in here has been reported to
is available. affect the promoter activity of this gene. It is likely that
The exact mechanism by which the uteroglobin G38A uteroglobin has substantial biological effects on renal
polymorphism affects only the patients at a high risk for cells in vitro and in vivo, although we have no data or
the progression to ESRD is unclear. knowledge to prove this opinion. The mechanism(s) of
In the previous report, Szelestei et al mentioned that uteroglobin action is likely to be even more complex as it
they could not exclude a blood pressure-effect for the also functions via a putative receptor-mediated pathway
association of the uteroglobin polymorphism and disease that is yet to be clearly defined.
progression of IgAN [15]. The incidence of hypertension The limitation of this study is that the association be-
in the patients with GG genotype also tended to be
tween the level of uteroglobin and the disease progres-
higher (but not statistically significant) than that in those
sion is not available. We have no data for the expressionwith other genotypes in this study. It is known that ute-
of uteroglobin in the kidney. Further study is requiredroglobin is a remarkable functional protein, and that
to clarify the functional mechanism of the role of thistransgenic mice that have been rendered deficient and
gene polymorphism. It is essential to elucidate the molec-humans who have been characterized as deficient in this
ular mechanism of uteroglobin’s functions in both physi-protein exhibit tendencies toward inflammatory, fibrotic,
ological and pathological situations.and oncologic diseases, demonstrating the potential of
Many studies of genetic factors for susceptibility or pro-this protein as a therapeutic agent [20]. The polymor-
gression of IgAN have been published, although no posi-phism at the 5 untranslated region of exon 1 in this gene
tive or negative association of these genetic candidateshas been shown to directly affect the expression of ute-
are useful for diagnostic or therapeutic purposes. Theyroglobin, although the gene construct with A at the 38th
site showed a rather decreased activity compared to that include genes for human lymphocyte antigens (HLA),
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Group on Progressive Renal Diseases. Am J Kidney Dis 29:526–complement, renin-angiotensin system, IgA immune sys-
532, 1997
tem, etc. [21]. 3. Galla JH: IgA nephropathy. Kidney Int 47:377–387, 1995
4. Szeto CC, Lai FM, To KF, et al: The natural history of immuno-In conclusion, these results demonstrate that the uter-
globulin a nephropathy among patients with hematuria and mini-oglobin G38A polymorphism affects the disease progres-
mal proteinuria. Am J Med 110:434–437, 2001
sion of IgAN especially in patients with hypertension 5. Rantala I, Mustonen J, Hurme M, et al: Pathogenetic aspects of
IgA nephropathy. Nephron 88:193–198, 2001and heavy proteinuria, which are clinical risk factors for
6. Scolari F, Amoroso A, Savoldi S, et al: Familial clustering of IgAprogression to ESRD. This indicates that antihyperten-
nephropathy: Further evidence in an Italian population. Am J
sive treatment and glucocorticoid treatment should be Kidney Dis 33:857–865, 1999
7. Hsu SI, Ramirez SB, Winn MP, et al: Evidence for genetic factorsadministered more extensively to the patients with GG
in the development and progression of IgA nephropathy. Kidneygenotype. Moreover, patients with both the GG geno-
Int 57:1818–1835, 2000
type of uteroglobin and clinical risk factors such as hyper- 8. Alamartine E, Sabatier JC, Guerin C, et al: Prognostic factors
in mesangial IgA glomerulonephritis: An extensive study with uni-tension and heavy proteinuria might be good candidates
variate and multivariate analyses. Am J Kidney Dis 18:12–19, 1991for new therapeutic strategies such as an uteroglobin-
9. Atger M, Savouret JF, Milgrom E: Synthesis, purification and
based therapy. characterization of a DNA complementary to uteroglobin messen-
ger RNA. J Steroid Biochem 13:1157–1162, 1980It is thought to be important to select the appropriate
10. Aoki A, Pasolli HA, Raida M, et al: Isolation of human uteroglo-class of antihypertensive agents according to the charac-
bin from blood filtrate. Mol Hum Reprod 2:489–497, 1996
teristics of the patients including—if the evidence is avail- 11. Mukherjee AB, Kundu GC, Mantile-Selvaggi G, et al: Uteroglo-
bin: A novel cytokine? Cell Mol Life Sci 55:771–787, 1999able—a genetic marker such as uteroglobin G38A. How-
12. Zheng F, Kundu GC, Zhang Z, et al: Uteroglobin is essential inever, we have no data to answer this matter. Moreover,
preventing immunoglobulin A nephropathy in mice. Nat Med 5:
we cannot completely exclude the possibility that some 1018–1025, 1999
13. Mukherjee AB, Kundu GC, Mandal AK, et al: Uteroglobin:biases existed in the population analyzed here, because
Physiological role in normal glomerular function uncovered bythe sample size of each stratified group was not suffi-
targeted disruption of the uteroglobin gene in mice. Am J Kidney
ciently large. To confirm the findings in our study, further Dis 32:1106–1120, 1998
14. Kim YS, Kang D, Kwon DY, et al: Uteroglobin gene polymor-investigation in a prospective trial with a large-scale pop-
phisms affect the progression of immunoglobulin A nephropathyulation will be needed.
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ics 11:299–305, 2001
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